Upneeq

Indications

Upneeq is specifically indicated for the treatment of acquired blepharoptosis. This condition occurs when the upper eyelid hangs lower than it should, which can affect a person's appearance or interfere with their field of vision.

Acquired blepharoptosis typically develops later in life and may be caused by several factors, including:

• Natural aging processes that cause the eyelid muscles to stretch or weaken.
• Previous eye surgeries.
• Certain medical conditions that affect the nerves or muscles of the eyelid.

Limitations of Use

It is important to note that Upneeq is intended for adults with acquired ptosis. It has not been studied or approved for use in treating congenital ptosis, which is a drooping eyelid that is present from birth.

Mechanism of Action

Upneeq contains oxymetazoline, a medication classified as an alpha-adrenergic agonist. It is specifically designed to treat acquired blepharoptosis, a condition where the upper eyelid droops due to muscle weakness or stretching over time.

The medication works through the following process:

• Targeting the Muscle: When the drops are applied to the eye, the active ingredient reaches the Mueller's muscle, also known as the superior tarsal muscle.
• Stimulation: Oxymetazoline triggers alpha-adrenergic receptors located within this involuntary muscle.
• Contraction: This stimulation causes the Mueller's muscle to contract and shorten.
• Eyelid Elevation: As the muscle contracts, it pulls the upper eyelid upward, resulting in a wider eye opening.

This mechanical lift is temporary and helps improve the field of vision for individuals whose eyelids have sagged. Because it targets an involuntary muscle, the lifting effect occurs without the patient needing to consciously flex their eyelid muscles.

Common Side Effects

The most frequently reported side effects of Upneeq are generally mild and affect the eyes or surrounding areas. These include:

• Eye redness (conjunctival hyperemia)
• Small areas of inflammation on the surface of the eye (punctate keratitis)
• Dry eye or blurred vision
• Eye pain or irritation at the time of application
• Headache
• Inflammation of the nose and throat (nasopharyngitis)

Serious Side Effects

Although rare, some individuals may experience more serious reactions. Seek medical advice if you notice:

• Severe eye pain, redness, or swelling
• Sudden changes in vision or seeing halos around lights
• Significant changes in blood pressure or heart rate
• Signs of a serious allergic reaction, such as a severe rash, swelling of the face or throat, or difficulty breathing

Because Upneeq is an alpha-adrenergic agonist, it may impact blood pressure. It should be used with caution by individuals with cardiovascular disease, unstable high blood pressure, or narrow-angle glaucoma.

Cardiovascular and Vascular Concerns

As an alpha-adrenergic agonist, Upneeq may affect blood pressure. Caution is recommended for individuals with cardiovascular disease, poorly controlled hypertension, or orthostatic hypotension. It may also worsen symptoms in patients with vascular insufficiency, such as Raynaud's phenomenon or thromboangiitis obliterans.

Risk of Angle-Closure Glaucoma

Upneeq may trigger angle-closure glaucoma in patients with narrow-angle glaucoma. Immediate medical evaluation is necessary if symptoms like sudden eye pain, redness, or blurred vision occur.

Underlying Medical Conditions

Eyelid drooping can be a sign of neurological or structural issues, including myasthenia gravis, Horner syndrome, or orbital masses. Upneeq may not be effective or appropriate if ptosis is caused by these underlying conditions rather than acquired blepharoptosis.

Proper Use and Hygiene

• The tip of the single-use container must not touch the eye or any surface to avoid contamination or injury.
• Contact lenses should be removed prior to use and may be reinserted 15 minutes after the drops are applied.
• Each container is for single use only and should be discarded after one application.

Pregnancy

There are no adequate clinical studies or data to determine if Upneeq poses a risk to a developing fetus or increases the chance of miscarriage. While the medication is applied topically to the eye, systemic absorption into the bloodstream is low, which may reduce potential exposure to the fetus. Because the risks are not fully known, it is important to discuss the use of this medication with a healthcare provider if you are pregnant or planning to become pregnant.

Breastfeeding

It is currently unknown whether oxymetazoline, the active ingredient in Upneeq, is excreted in human breast milk. There is also no data available regarding the effects of the medication on a nursing infant or its impact on milk production. Because many drugs can pass into breast milk, caution is typically advised. Individuals who are breastfeeding should consult with their healthcare provider to weigh the potential benefits against any risks to the infant.

Dosage Form

Upneeq is supplied as a sterile ophthalmic solution. The liquid is clear and may range from colorless to a light straw color.

Strengths and Packaging

• Single-Use Containers: This medication is packaged in individual plastic containers designed for one-time use. Each container provides enough solution for a single dose in one or both eyes.
• Concentration: The solution contains a specific concentration of oxymetazoline hydrochloride (0.1%).
• Storage Packaging: The single-use containers are typically distributed in foil pouches within a carton.

Because the containers do not contain preservatives, any solution remaining in a container after the initial application must be discarded immediately.

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%) in July 2020. It was the first pharmacological treatment approved for acquired blepharoptosis.

Approved Indications

Upneeq is specifically indicated for the treatment of acquired blepharoptosis in adults. This condition involves a drooping of the upper eyelid that occurs later in life, often due to the weakening of the eyelid muscles. It is not indicated for the treatment of congenital ptosis, which is a drooping eyelid present from birth.

Regulatory Status and Safety

Upneeq is a prescription-only medication. At this time, there are no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) programs required by the FDA for this drug. The FDA monitors the safety of the medication through standard post-marketing surveillance and reporting systems.

Insurance and Coverage

Upneeq is a prescription medication used to treat acquired blepharoptosis (droopy eyelids). Because this condition is frequently viewed as a cosmetic concern rather than a medical necessity, many private insurance plans and Medicare do not provide coverage for the drug. Patients should consult their insurance provider to determine if the medication is included in their formulary or if a prior authorization is required.

Factors Affecting Price

The total price of Upneeq is influenced by the quantity of medication purchased and the pharmacy used. It is typically supplied in cartons containing 30 or 45 single-use foil pouches. As there is currently no generic version of this specific oxymetazoline ophthalmic solution, the cost remains at the brand-name level. Factors that may impact the final price include:

• The specific supply size (number of single-use containers).
• Pharmacy-specific dispensing fees and markups.
• Whether the medication is obtained through a traditional retail pharmacy or a specialty pharmacy.

Financial Assistance and Savings

Since out-of-pocket costs can be high, some patients may utilize manufacturer savings programs or pharmacy discount cards to reduce the expense. Some healthcare providers may also coordinate with specialty pharmacies that offer the medication at a consistent price point for patients without insurance coverage.